Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy Trust for Rheumatology Research (KTRR) has pledged a minimum of £20M over five years to the Kennedy Institute of Rheumatology at the University of Oxford to support pioneering research into chronic inflammatory disease.

Kennedy Institute and Kennedy Trust for Rheumatology Research Logos

 

Support from the Kennedy Trust has allowed us to attract exciting new investigators, establish new technologies, and develop an outstanding graduate training programme.
- Professor Fiona Powrie

The support from the KTRR will further the Kennedy Institute's ambition to harness discovery research and identification of disease pathways for application in the clinic, driving innovative new therapies to benefit patients.

Director of the Institute Professor Fiona Powrie says: "I am delighted that the Kennedy Trust have agreed to extend funding for the Institute for a further five years. With their support we have been able to attract exciting new investigators, establish new technologies, and develop an outstanding graduate training programme.

The renewed, significant funding will allow us to deliver the next phase of our strategy, including capacity building in imaging, microbiome science, informatics, and clinical research to bridge the gap between basic and translational research."

The new agreement extends the KTRR's support to the Institute beyond the current agreement which expires in 2021. The funding is awarded through individual grants and subjected to independent review on a regular basis.

Pierre Espinasse, KTRR's General Manager , says: The quality of the work undertaken at the Institute since its move to Oxford is hugely impressive and the Trust is delighted to be able to reaffirm its longterm commitment to supporting the Institute through this new agreement.

The KTRR funded the Kennedy Institute's move to Oxford from London in 2013, contributing £22M to the new building located on the University of Oxford's Old Road Campus, as well as a £5M equipment grant.

The initial agreement also committed £3M support per annum from 2011-2021 enabling the recruitment of new faculty to the Institute, as well as the development of state-of-the-art technology platforms to support key areas of research.

More broadly, the KTRR provides financial support for scientific research into improving ill health caused by rheumatic and related musculoskeletal and inflammatory diseases, particularly in areas that could benefit from long-term coordinated support.

 

Similar stories

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

Researchers funded to cure – rather than manage – inflammatory disease

Researchers from the Kennedy Institute of Rheumatology will join international partners in a bid to transform how chronic inflammatory disease is treated.

Mark Coles receives funding to tackle viral threats

Professor Mark Coles is leading one of three innovative University of Oxford research projects that have secured funding through the UK's Advanced Research and Invention Agency (ARIA) to transform how we protect against respiratory viruses.

Major MRC funding for Irina Udalova to unravel neutrophil behaviour across immune pathologies

Prof Irina Udalova has received a programme grant of £2.7M from the Medical Research Council (MRC) to investigate how neutrophils – a type of white blood cell that forms the body’s first line of defence – adapt their behaviour to tissue requirements and contribute to immune diseases, leading to the development of a new class of neutrophil-targeted therapeutics.

£3M study led by patient voices targets pain in inflammatory arthritis

Researchers across the UK are banding together to tackle one of the largest unmet clinical needs in inflammatory arthritis, pain reduction, in a new £3m research programme funded by Arthritis UK.

Oxford and GSK launch Experimental Medicine Collaboration

GSK invests £10 million over five years to establish the Experimental Medicine Collaboration with the University of Oxford.